Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sargent

Showing results (191-200 of 514) with videos related to

Pageof 52
Sort By:
The Cochrane Database of Systematic Reviews|November 1, 2001
Removal of nail polish and finger rings to prevent surgical infectionV A Arrowsmith, J A Maunder, R J Sargent, et al.
The New England Journal of Medicine|July 14, 2001
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancerD J Sargent, D Niedzwiecki, M J O'Connell, et al.
Nature Reviews. Clinical Oncology|September 4, 2013
Drug rechallenge and treatment beyond progression--implications for drug resistanceElizabeth A Kuczynski, Daniel J Sargent, Axel Grothey, et al.
CNS Drug Reviews|July 28, 2001
BTS 72664-- a novel CNS drug with potential anticonvulsant, neuroprotective, and antimigraine propertiesS L Smith, K S Thompson, B J Sargent, et al.
Biometrics|March 3, 2011
Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trialsBrian P Hobbs, Bradley P Carlin, Sumithra J Mandrekar, et al.
Nature Reviews. Clinical Oncology|April 7, 2010
Biomarkers and surrogate end points--the challenge of statistical validationMarc Buyse, Daniel J Sargent, Axel Grothey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1987
Sequence of protective epitopes of streptococcal M proteins shared with cardiac sarcolemmal membranesS J Sargent, E H Beachey, C E Corbett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Alternate endpoints for screening phase II studiesNeesha Dhani, Dongsheng Tu, Daniel J Sargent, et al.
Bayesian Analysis|April 5, 2016
Flexible Bayesian survival modeling with semiparametric time-dependent and shape-restricted covariate effectsThomas A Murray, Brian P Hobbs, Daniel J Sargent, et al.
Neurobiology of Disease|July 30, 2013
From preclinical to clinical development: the example of a novel treatment for obesityNicholas A Moore, Bruce J Sargent, Peter R Guzzo, et al.
Pageof 52

Showing results (191-200 of 514) with videos related to

Sort By:
Pageof 52
The Cochrane Database of Systematic Reviews|November 1, 2001
Removal of nail polish and finger rings to prevent surgical infectionV A Arrowsmith, J A Maunder, R J Sargent, et al.
The New England Journal of Medicine|July 14, 2001
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancerD J Sargent, D Niedzwiecki, M J O'Connell, et al.
Nature Reviews. Clinical Oncology|September 4, 2013
Drug rechallenge and treatment beyond progression--implications for drug resistanceElizabeth A Kuczynski, Daniel J Sargent, Axel Grothey, et al.
CNS Drug Reviews|July 28, 2001
BTS 72664-- a novel CNS drug with potential anticonvulsant, neuroprotective, and antimigraine propertiesS L Smith, K S Thompson, B J Sargent, et al.
Biometrics|March 3, 2011
Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trialsBrian P Hobbs, Bradley P Carlin, Sumithra J Mandrekar, et al.
Nature Reviews. Clinical Oncology|April 7, 2010
Biomarkers and surrogate end points--the challenge of statistical validationMarc Buyse, Daniel J Sargent, Axel Grothey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1987
Sequence of protective epitopes of streptococcal M proteins shared with cardiac sarcolemmal membranesS J Sargent, E H Beachey, C E Corbett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Alternate endpoints for screening phase II studiesNeesha Dhani, Dongsheng Tu, Daniel J Sargent, et al.
Bayesian Analysis|April 5, 2016
Flexible Bayesian survival modeling with semiparametric time-dependent and shape-restricted covariate effectsThomas A Murray, Brian P Hobbs, Daniel J Sargent, et al.
Neurobiology of Disease|July 30, 2013
From preclinical to clinical development: the example of a novel treatment for obesityNicholas A Moore, Bruce J Sargent, Peter R Guzzo, et al.
Pageof 52